CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice

Cerebral Cortex

Volumn 25, Issue 1, 2015, Pages 35-45

  Lopez Rodriguez, Ana Belen ^a,e   Siopi, Eleni ^b   Finn, David P ^d   Marchand Leroux, Catherine ^b   Garcia Segura, Luis M ^e   Jafarian Tehrani, Mehrnaz ^b,c   Viveros, Maria Paz ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^c CNRS   (France)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^e INSTITUTO CAJAL   (Spain)

Author keywords

Cannabinoid system; Diffuse axonal injury; Microglial activation; Minocycline; Neuroprotection; Traumatic brain injury

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; MINOCYCLINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; IODOPRAVADOLINE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EDEMA; CELL ACTIVATION; CONTROLLED STUDY; DIFFUSE AXONAL INJURY; DRUG MECHANISM; MALE; MICROGLIA; MOUSE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN INJURY; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; NERVE FIBER; PATHOLOGY;

ANIMALS; AXONS; BRAIN; BRAIN EDEMA; BRAIN INJURIES; CANNABINOID RECEPTOR ANTAGONISTS; INDOLES; MALE; MICE; MICROGLIA; MINOCYCLINE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84922361746     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bht202     Document Type: Article

References (88)

1. Bales JW, Wagner AK, Kline AE, Dixon CE. 2009. Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. Neurosci Biobehav Rev. 33:981-1003.
2. Barzó P, Marmarou A, Fatouros P, Hayasaki K, Corwin F. 1997. Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging. J Neurosurg. 87:900-907.
3. Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF. 2008. Pharmacology of traumatic brain injury: where is the "golden bullet"? Mol Med. 14:731-740.
4. Boto GR, Gómez PA, De la Cruz J, Lobato RD. 2009. A historical analysis of severe head injury. Neurosurg Rev. 32:343-353.
5. Brooks DN. 1972. Memory and head injury. J Nerv Ment Dis. 155:350-355.
6. Cabral GA, Marciano-Cabral F. 2005. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol. 78:1192-1197.
7. Cernak I. 2005. Animal models of head trauma. NeuroRx. 2:410-422.
8. Chen Y, Buck J. 2000. Cannabinoids protect ells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther. 293:807-812.
9. Chin C-L, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J et al. 2008. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol. 153:367-379.
10. Chodobski A, Zink BJ, Szmydynger-Chodobska J. 2011. Blood-brain barrier pathophysiology in traumatic brain injury. Trans Stroke Res. 2:492-516.
11. Chu L-S, Fang S-H, Zhou Y, Yin Y-J, Chen W-Y, Li J-H, Sun J, Wang M-L, Zhang W-P, Wei E-Q. 2010. Minocycline inhibits 5-lipoxygenase expression and accelerates functional recovery in chronic phase of focal cerebral ischemia in rats. Life Sci. 86:170-177.
12. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan W-B. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 8:752-758.
13. d'Avila JC, Lam TI, Bingham D, Shi J, Won SJ, Kauppinen TM, Massa S, Liu J, Swanson RA. 2012. Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflammation. 9:31.
14. Di Filippo C, Rossi F, Rossi S, Amico MD. 2004. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine. J Leukoc Biol. 75:453-459.
15. Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J. 2007. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci. 27:9537-9544.
16. Diz-Chaves Y, Pernia O, Carrero P, Garcia-Segura LM. 2012. Prenatal stress causes alterations in the morphology of microglia and the inflammatory response of the hippocampus of adult female mice. J Neuroinflammation. 9:71.
17. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R et al. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 49:67-79.
18. Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI. 2011. Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J Neurotrauma. 28:973-981.
19. Emilien G, Waltregny A. 1996. Traumatic brain injury, cognitive and emotional dysfunction. Impact of clinical neuropsychology research. Acta Neurol Belg. 96:89-101.
20. Esposito G, Izzo AA, Di Rosa M, Iuvone T. 2001. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem. 78: 835-841.
21. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. 2012. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation. 9:62.
22. Flierl Ma, Stahel PF, Beauchamp KM, Morgan SJ, Smith WR, Shohami E. 2009. Mouse closed head injury model induced by a weight-drop device. Nat Protoc. 4:1328-1337.
23. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. 2010. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol. 224:37-47.
24. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, Perez-Alvarez S, De Mera RMMF, Jordan MJ, Aguirre N, Galindo MF et al. 2010. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol. 79:239-250.
25. Gennarelli TA. 1994. Animate models of human head injury. J Neurotrauma. 11:357-368.
26. Girgis H, Palmier B, Croci N, Soustrat M, Plotkine M, Marchand-Leroux C. 2013. Effects of selective and non-selective cyclooxygenase inhibition against neurological deficit and brain oedema following closed head injury in mice. Brain Res. 1491:78-87.
27. González JC, Egea J, Del Carmen Godino M, Fernandez-Gomez FJ, Sánchez-Prieto J, Gandía L, García AG, Jordán J, Hernández-Guijo JM. 2007. Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. Eur J Neurosci. 26:2481-2495.
28. Hanisch U-K, Kettenmann H. 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 10:1387-1394.
29. Hanstock CC, Faden AI, Bendall MR, Vink R. 1994. Diffusion-weighted imaging differentiates ischemic tissue from traumatized tissue. Stroke. 25:843-848.
30. Hellal F, Pruneau D, Palmier B, Faye P, Croci N, Plotkine M, Marchand-Verrecchia C. 2003. Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J Neurotrauma. 20:841-851.
31. Herkenham M. 1992. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci. 654:19-32.
32. Homsi S, Federico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2009. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res. 1291:122-132.
33. Homsi S, Piaggio T, Croci N, Noble F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2010. Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study. J Neurotrauma. 27:911-921.
34. Iwata A, Stys PK, Wolf JA, Chen X-H, Taylor AG, Meaney DF, Smith DH. 2004. Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors. J Neurosci. 24:4605-4613.
35. Klein TW, Lane B, Newton CA, Friedman H. 2000. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 225:1-8.
36. Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z. 2011. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 163:1507-1519.
37. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. 2010. Cannabinoids δ9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-Activated NF-κB and Interferon-β/ STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 285:1616-1626.
38. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. 2005. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem. 94:819-827.
39. Lazovic J, Basu A, Lin H-W, Rothstein RP, Krady JK, Smith MB, Levison SW. 2005. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke. 36:2226-2231.
40. López Rodríguez AB, Mateos Vicente B, Romero-Zerbo SY, Rodriguez-Rodriguez N, Bellini MJ, Rodriguez de Fonseca F, Bermudez-Silva FJ, Azcoitia I, Garcia-Segura LM, Viveros M-P. 2011. Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors. Cerebr Cortex. 21:2046-2055.
41. Lucas S-M, Rothwell NJ, Gibson RM. 2006. The role of inflammation in CNS injury and disease. Br J Pharmacol. 147:S232-S240.
42. Mackie K. 2006. Cannabinoid receptors as therapeutic targets. Ann Rev Pharmacol Toxicol. 46:101-122.
43. Marco EM, García-Gutiérrez MS, Bermúdez-Silva F-J, Moreira FA, Guimarães F, Manzanares J, Viveros M-P. 2011. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci. 5:63.
44. Markovic DS, Vinnakota K, Van Rooijen N, Kiwit J, Synowitz M, Glass R, Kettenmann H. 2011. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav Immun. 25:624-628.
45. Marmarou A. 2003. Pathophysiology of traumatic brain edema: current concepts. Acta Neurochir Suppl. 86:7-10.
46. Masson F, Thicoipe M, Aye P, Mokni T, Senjean P, Schmitt V, Dessalles PH, Cazaugade M, Labadens P. 2001. Epidemiology of severe brain injuries: a prospective population-based study. J Trauma. 51: 481-489.
47. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishiwari K, Makriyannis A, Salamone JD. 2003. The cannabinoid CB1 antagonists SR 141716A and AM 51 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol. 14:583-588.
48. McLean A, Temkin NR, Dikmen S, Wyler AR. 1983. The behavioral sequelae of head injury. J Clin Neuropsychol. 5:361-376.
49. Micale V, Mazzola C, Drago F. 2007. Endocannabinoids and neurodegenerative diseases. Pharmacol Res. 56:382-392.
50. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci. 22:9742-9753.
51. Möller T, Hanisch UK, Ransom BR. 2000. Thrombin-induced activation of cultured rodent microglia. J Neurochem. 75:1539-1547.
52. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 19:2987-2995.
53. Nikodemova M, Duncan ID, Watters JJ. 2006. Minocycline exerts inhibitory effects on multiple mitogen-Activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J Neurochem. 96:314-323.
54. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E. 2006. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 22:257-264.
55. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:527-531.
56. Paulsen K, Tauber S, Timm J, Goelz N, Dumrese C, Stolzing A, Hass R, Ullrich O. 2011. The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins. Cell Commun Signal. 9:33.
57. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. 4th ed. New York: Elsevier.
58. Piomelli D. 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 4:873-884.
59. Plane JM, Shen Y, Pleasure DE, Deng W. 2010. Prospects for minocycline neuroprotection. Arch Neurol. 67:1442-1448.
60. Povlishock JT, Hayes RL, Michel ME, McIntosh TK. 1994. Workshop on animal models of traumatic brain injury. J Neurotrauma. 11:723-732.
61. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. 1994. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 57:419-425.
62. Rochat L, Beni C, Billieux J, Azouvi P, Annoni J-M, Van der Linden M. 2010. Assessment of impulsivity after moderate to severe traumatic brain injury. Neuropsychol Rehabil. 20:778-797.
63. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, Villarreal F. 2008. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 52:1086-1094.
64. Royo NC, Wahl F, Stutzmann JM. 1999. Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat. Neuroreport. 10:1363-1367.
65. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. 2001. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 48: 1393-1399.
66. Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I. 2000. Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett. 472:39-44.
67. Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O. 2011. The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol. 163:1391-1401.
68. Shenaq M, Kassem H, Peng C, Schafer S, Ding JY, Fredrickson V, Guthikonda M, Kreipke CW, Rafols JA, Ding Y. 2012. Neuronal damage and functional deficits are ameliorated by inhibition of aquaporin and HIF1α after traumatic brain injury (TBI). J Neurol Sci. 323: 134-140.
69. Siopi E, Calabria S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2012. Minocycline restores olfactory bulb volume and olfactory behavior after traumatic brain injury in mice. J Neurotrauma. 29: 354-361.
70. Siopi E, Cho AH, Homsi S, Croci N, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2011. Minocycline restores sAPPα levels and reduces the late histopathological consequences of traumatic brain injury in mice. J Neurotrauma. 28:2135-2143.
71. Siopi E, Llufriu-Dabén G, Cho AH, Vidal-Lletjós S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2013. Etazolate, an α-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology. 67C:183-192.
72. Siopi E, Llufriu-Dabén G, Fanucchi F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. 2012. Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline. Neurosci Lett. 511:110-115.
73. Smith SR, Terminelli C, Denhardt G. 2000. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther. 293:136-150.
74. Soares HD, Hicks RR, Smith D, McIntosh TK. 1995. Inflammatory leukocytic recruitment and diffuse neuronal degeneration are separate pathological processes resulting from traumatic brain injury. J Neurosci. 15:8223-8233.
75. Stella N. 2010. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 58:1017-1030.
76. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 21:2580-2588.
77. Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-Aspartate neurotoxicity by inhibiting microglia. J Immunol. 166:7527-7533.
78. Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J. 2009. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-Amyloid removal by human macrophages. Brain Res. 1283:148-154.
79. Tominaga T, Ohnishi ST. 1989. Interrelationship of brain edema, motor deficits, and memory impairment in rats exposed to focal ischemia. Stroke. 20:513-518.
80. Vanezis P, Chan KK, Scholtz CL. 1987. White matter damage following acute head injury. Forensic Sci Int. 35:1-10.
81. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. 2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 23:1398-1405.
82. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT. 2006. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care. 5:71-78.
83. Weibel ER. 1979. Stereological methods. Vol. 1. Practical methods for biological morphometry. London: Academic Press.
84. Werner C, Engelhard K. 2000. Pathophysiology of traumatic brain injury. Crit Care Nurs Q. 23:14-25.
85. World Health Organization. 2006. The world health report 2006: working together for health. Geneva: WHO Press.
86. Wortzel HS, Arciniegas DB. 2012. Treatment of post-traumatic cognitive impairments. Curr Treat Options Neurol. 14:493-508.
87. Wu X, Hu J, Zhuo L, Fu C, Hui G, Wang Y, Yang W, Teng L, Lu S, Xu G. 2008. Epidemiology of traumatic brain injury in eastern China, 2004: a prospective large case study. J Trauma. 4: 1313-1319.
88. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF. 2009. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol. 4:249-259.